PRESS RELEASE published on 01/18/2024 at 22:50, 8 months 1 day ago CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China Bausch Health Companies Inc. and Solta Medical have announced the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA), marking a significant milestone for Solta Medical and opening up significant opportunities in the Chinese market. The approval represents a substantial achievement for the R&D and Regulatory Teams, signifying continued growth for the Thermage technology. The non-invasive treatment, which uses radiofrequency technology to tighten and improve the texture of the skin, has seen over two million treatments globally and is now set to continue its growth in China. The approval paves the way for delivering proven technology to the Chinese market and signifies a crucial breakthrough in the medical aesthetics market. Thermage FLX NMPA Approval Medical Aesthetics Market TR-4 Return Pad China
PRESS RELEASE published on 01/18/2024 at 14:00, 8 months 1 day ago Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China Bausch Health Companies Inc. and Solta Medical announce the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA). This approval represents a significant breakthrough in one of the largest medical aesthetics markets, allowing the companies to continue the momentum of the growth of Thermage in China. The non-invasive treatment, Thermage, is a versatile and effective technology that can be used on all skin types and genders, delivering exceptional results for patients. For more information, visit www.bauschhealth.com and www.solta.com. Thermage FLX NMPA Approval Medical Aesthetics Market Non-invasive Treatment Bausch Health Companies
PRESS RELEASE published on 01/08/2024 at 06:00, 8 months 11 days ago Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals presented oral arguments at the U.S. Court of Appeals for the Federal Circuit regarding the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. No ruling was issued following the oral arguments. The company continues to advocate for the safety of patients benefiting from XIFAXAN® (rifaximin) 550 mg tablets, indicated for hepatic encephalopathy recurrence and irritable bowel syndrome with diarrhea. Salix Pharmaceuticals focuses on the prevention and treatment of gastrointestinal diseases for over 30 years and markets its products to U.S. health care providers. On the other hand, Bausch Health Companies Inc. is a global diversified pharmaceutical company with a mission to improve people's lives through various health care products, primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The news release contains forward-looking statements about Bausch Health's future performance and the appeal with respect to intellectual property. The actual results are subject to certain risks and uncertainties. For more information, visit www.bauschhealth.com and connect with them on Twitter and LinkedIn. Bausch Health Companies Inc. Salix Pharmaceuticals Gastrointestinal Diseases XIFAXAN Oral Arguments
PRESS RELEASE published on 12/21/2023 at 13:00, 8 months 29 days ago Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
PRESS RELEASE published on 12/18/2023 at 14:00, 9 months 1 day ago DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
PRESS RELEASE published on 12/18/2023 at 14:00, 9 months 1 day ago La lotion DUOBRII(MC) pour le traitement du psoriasis en plaques modéré ou sévère maintenant couverte par le régime public d’assurance médicaments du Québec
PRESS RELEASE published on 12/05/2023 at 14:00, 9 months 14 days ago Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day Salix Pharmaceuticals, Bausch Health Companies Inc., U.S. Pain Foundation, and IFFGD collaborate to establish the first annual Opioid-Induced Constipation (OIC) Awareness Day to raise awareness about the often-overlooked side effect of opioids and provide a platform for patients, caregivers, and healthcare providers to discuss and address OIC Healthcare Providers Chronic Pain Opioid-Induced Constipation Awareness Day Patient Advocacy
PRESS RELEASE published on 11/10/2023 at 14:00, 10 months 9 days ago The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
PRESS RELEASE published on 11/10/2023 at 06:00, 10 months 9 days ago CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
PRESS RELEASE published on 11/08/2023 at 14:00, 10 months 11 days ago As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
Published on 09/19/2024 at 23:15, 2 hours 36 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 2 hours 51 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 23:00, 2 hours 51 minutes ago Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Published on 09/19/2024 at 21:09, 4 hours 41 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 7 hours 6 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 7 hours 48 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 7 hours 58 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 7 hours 58 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 8 hours 6 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 8 hours 6 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 8 hours 6 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)